Effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) on urinary glucose excretion in type 2 diabetes
- Conditions
- type 2 diabetesMetabolic and Endocrine - Diabetes
- Registration Number
- ACTRN12623001184662
- Lead Sponsor
- The University of Adelaide
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Type 2 diabetes (American Diabetes Association criteria) treated by diet and/or up to two oral glucose-lowering agents (on stable doses over the last 3 months) except for SGLT2 inhibitors or DPP-4 inhibitors
- Body mass index (BMI) between 20 to 40 kg/m2
- Males and females, aged from 18 to 79 years
- Glycated haemoglobin (HbA1c) between 6.0% to 10.0%
- Haemoglobin above the lower limit of the normal range (ie. above 135 g/L for men and 115 g/L for women), and ferritin above the lower limit of normal (ie. above 30 mg/mL for men and 20 mg/mL for women)
- Evidence of drug abuse, consumption of more than 20 g alcohol or 10 cigarettes on a daily basis
- History of any form of heart disease or symptoms of syncope or pre-syncope (including feeling lightheaded or dizzy, feeling unsteady when standing, unexplained falls, fainting, unexplained changes in vision, such as blurring or tunnel vision)
- Other significant illness, including epilepsy, cardiovascular or respiratory disease
- Impaired renal or liver function (as assessed by calculated creatinine clearance less than 60 mL/min or abnormal liver function tests (more than 2 times upper limit of normal range))
- Donation of blood within the previous 3 months
- Participation in any other research studies within the previous 3 months
- Inability to give informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method